Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Delanoy

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Gynecologic Oncology|December 15, 2022
Response to first line platinum-based chemotherapy in mismatch repair deficient (MMRd)/ microsatellite instability high (MSI-high) endometrial carcinomaEmeline Colomba, Jérôme Alexandre, Gwénaël Le Teuff, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 22, 2023
Patterns of recurrence in surgically treated women for TP53-mutated endometrial carcinomasFlore-Anne Pain, Guillaume Beinse, Henri Azaïs, et al.
Gynecologic Oncology|June 1, 2022
Potential competing risk of death in older high-risk endometrial carcinoma patients: Results from a multicentric retrospective cohortViolaine Gorgeu, Bruno Borghese, Meriem Koual, et al.
Annales De Pathologie|February 13, 2020
[Hereditary breast and ovarian cancer syndrome: Diagnosis and therapeutic implications]Meriem Koual, Géraldine Perkins, Nicolas Delanoy, et al.
Clinical Genitourinary Cancer|March 19, 2018
Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted AgentsAntoine Angelergues, Eleni Efstathiou, Revekka Gyftaki, et al.
British Journal of Cancer|June 25, 2022
Discovery and validation of a transcriptional signature identifying homologous recombination-deficient breast, endometrial and ovarian cancersGuillaume Beinse, Pierre-Alexandre Just, Marie-Aude Le Frere Belda, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|May 11, 2023
Prognostic impact of cytoreductive surgery conducted with primary intent, versus cytoreductive surgery after neoadjuvant chemotherapy, in the management of patients with advanced epithelial ovarian cancers: a multicentre, propensity score-matched study from the FRANCOGYN groupHenri Wohrer, Meriem Koual, Enrica Bentivegna, et al.
Gynecologic Oncology|January 16, 2022
Development and validation of a RNAseq signature for prognostic stratification in endometrial cancerGuillaume Beinse, Marie-Aude Le Frere Belda, Pierre-Alexandre Just, et al.
Cancers|February 11, 2023
A Suggested Modification to FIGO Stage IV Epithelial Ovarian CancerMarie Métairie, Louise Benoit, Meriem Koual, et al.
Gynecologic Oncology|January 27, 2023
Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trialGwénaël Ferron, Gaëtan De Rauglaudre, Stéphanie Becourt, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Gynecologic Oncology|December 15, 2022
Response to first line platinum-based chemotherapy in mismatch repair deficient (MMRd)/ microsatellite instability high (MSI-high) endometrial carcinomaEmeline Colomba, Jérôme Alexandre, Gwénaël Le Teuff, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 22, 2023
Patterns of recurrence in surgically treated women for TP53-mutated endometrial carcinomasFlore-Anne Pain, Guillaume Beinse, Henri Azaïs, et al.
Gynecologic Oncology|June 1, 2022
Potential competing risk of death in older high-risk endometrial carcinoma patients: Results from a multicentric retrospective cohortViolaine Gorgeu, Bruno Borghese, Meriem Koual, et al.
Annales De Pathologie|February 13, 2020
[Hereditary breast and ovarian cancer syndrome: Diagnosis and therapeutic implications]Meriem Koual, Géraldine Perkins, Nicolas Delanoy, et al.
Clinical Genitourinary Cancer|March 19, 2018
Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted AgentsAntoine Angelergues, Eleni Efstathiou, Revekka Gyftaki, et al.
British Journal of Cancer|June 25, 2022
Discovery and validation of a transcriptional signature identifying homologous recombination-deficient breast, endometrial and ovarian cancersGuillaume Beinse, Pierre-Alexandre Just, Marie-Aude Le Frere Belda, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|May 11, 2023
Prognostic impact of cytoreductive surgery conducted with primary intent, versus cytoreductive surgery after neoadjuvant chemotherapy, in the management of patients with advanced epithelial ovarian cancers: a multicentre, propensity score-matched study from the FRANCOGYN groupHenri Wohrer, Meriem Koual, Enrica Bentivegna, et al.
Gynecologic Oncology|January 16, 2022
Development and validation of a RNAseq signature for prognostic stratification in endometrial cancerGuillaume Beinse, Marie-Aude Le Frere Belda, Pierre-Alexandre Just, et al.
Cancers|February 11, 2023
A Suggested Modification to FIGO Stage IV Epithelial Ovarian CancerMarie Métairie, Louise Benoit, Meriem Koual, et al.
Gynecologic Oncology|January 27, 2023
Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trialGwénaël Ferron, Gaëtan De Rauglaudre, Stéphanie Becourt, et al.
Pageof 4